|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cress RD, Chen YS, Morris CR, Petersen M
and Leiserowitz GS: Characteristics of long-term survivors of
epithelial ovarian cancer. Obstet Gynecol. 126:491–497. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eitan R, Kushnir M, Lithwick-Yanai G,
David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S and
Levavi H: Tumor microRNA expression patterns associated with
resistance to platinum based chemotherapy and survival in ovarian
cancer patients. Gynecol Oncol. 114:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang N, Kaur S, Volinia S, Greshock J,
Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, et al:
MicroRNA microarray identifies Let-7i as a novel biomarker and
therapeutic target in human epithelial ovarian cancer. Cancer Res.
68:10307–10314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian S, Zhang M, Chen X, Liu Y and Lou G:
MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by
targeting ABCB1. Oncotarget. 7:87091–87099. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu X, Shen H, Yin X, Long L, Xie C, Liu
Y, Hui L, Lin X, Fang Y, Cao Y, et al: miR-186 regulation of Twist1
and ovarian cancer sensitivity to cisplatin. Oncogene. 35:323–332.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Jaarsveld MT, Helleman J, Boersma AW,
van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH,
Berns EM, Verweij J, et al: miR-141 regulates KEAP1 and modulates
cisplatin sensitivity in ovarian cancer cells. Oncogene.
32:4284–4293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li N, Yang L, Wang H, Yi T, Jia X, Chen C
and Xu P: miR-130a and miR-374a function as novel regulators of
cisplatin resistance in human ovarian cancer A2780 cells. PLoS One.
10:e01288862015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Luo L, Zheng X and Yu T: An
advanced orthotopic ovarian cancer model in mice for therapeutic
trials. Biomed Res Int. 2016:25857872016.PubMed/NCBI
|
|
13
|
Lim LP, Lau NC, Weinstein EG, Abdelhakim
A, Yekta S, Rhoades MW, Burge CB and Bartel DP: The microRNAs of
Caenorhabditis elegans. Genes Dev. 17:991–1008. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shatseva T, Lee DY, Deng Z and Yang BB:
MicroRNA miR-199a-3p regulates cell proliferation and survival by
targeting caveolin-2. J Cell Sci. 124:2826–2836. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Minna E, Romeo P, De Cecco L, Dugo M,
Cassinelli G, Pilotti S, Degl'Innocenti D, Lanzi C, Casalini P,
Pierotti MA, et al: miR-199a-3p displays tumor suppressor functions
in papillary thyroid carcinoma. Oncotarget. 5:2513–2528. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu C, Xing M, Wang L and Zhang K:
miR-199a-3p downregulation in thyroid tissues is associated with
invasion and metastasis of papillary thyroid carcinoma. Br J Biomed
Sci. 74:90–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wala SJ, Karamchandani JR, Saleeb R, Evans
A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, et al:
An integrated genomic analysis of papillary renal cell carcinoma
type 1 uncovers the role of focal adhesion and extracellular matrix
pathways. Mol Oncol. 9:1667–1677. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen R, Alvero AB, Silasi DA, Kelly MG,
Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T and Mor G:
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in
ovarian cancer cells. Oncogene. 27:4712–4723. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Z, Ting Z, Li Y, Chen G, Lu Y and Hao
X: microRNA-199a is able to reverse cisplatin resistance in human
ovarian cancer cells through the inhibition of mammalian target of
rapamycin. Oncol Lett. 6:789–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Liu Q, Gao Q, Luo Y, Li Q and Chen
J: Involvement of miR-199a in cisplatin resistance of ovarian
cancer cell through modulating expression of mTOR. Zhonghua Yi Xue
Za Zhi. 95:2705–2708. 2015.(In Chinese). PubMed/NCBI
|
|
21
|
Qu F, Zheng J, Gan W, Lian H, He H, Li W,
Yuan T, Yang Y, Li X, Ji C, et al: MiR-199a-3p suppresses
proliferation and invasion of prostate cancer cells by targeting
Smad1. Oncotarget. 8:52465–52473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghosh A, Dasgupta D, Ghosh A, Roychoudhury
S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, et al:
MiRNA199a-3p suppresses tumor growth, migration, invasion and
angiogenesis in hepatocellular carcinoma by targeting VEGFA,
VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 8:e27062017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Xia X, Ji J, Ma J, Tao L, Mo L and
Chen W: MiR-199a-3p enhances cisplatin sensitivity of
cholangiocarcinoma cells by inhibiting mTOR signaling pathway and
expression of MDR1. Oncotarget. 8:33621–33630. 2017.PubMed/NCBI
|
|
24
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri
L: MiR-199a-3p regulates mTOR and c-Met to influence the
doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.
70:5184–5193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan X, Zhou S, Zheng M, Deng X, Yi Y and
Huang T: MiR-199a-3p enhances breast cancer cell sensitivity to
cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother.
88:507–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
LaPointe VL, Verpoorte A and Stevens MM:
The changing integrin expression and a role for integrin β8 in the
chondrogenic differentiation of mesenchymal stem cells. PLoS One.
8:e820352013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cabodi S, Di Stefano P, Leal Mdel P,
Tinnirello A, Bisaro B, Morello V, Damiano L, Aramu S, Repetto D,
Tornillo G and Defilippi P: Integrins and signal transduction. Adv
Exp Med Biol. 674:43–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cabodi S, del Pilar Camacho-Leal M, Di
Stefano P and Defilippi P: Integrin signalling adaptors: Not only
figurants in the cancer story. Nat Rev Cancer. 10:858–870. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang WW, Wang YB, Wang DQ, Lin Z and Sun
RJ: Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance
of human hepatic cancer HepG2/G cell line. Int J Clin Exp Med.
8:3063–3071. 2015.PubMed/NCBI
|
